The Office of U.S. Trade Representative (USTR) announced today the determination to “extend certain product exclusions and to make further modifications to remove Section 301 duties from additional medical-care products to address COVID-19.”  In a notice posted to it’s website, the USTR “determined that maintaining or re-imposing additional duties on certain products subject to the action no longer is appropriate and that the application of additional duties to these products could impact U.S. preparedness to address COVID-19.”

The USTR indicated that the extensions of the products will extend the exclusions through March 31, 2021. The modifications to exclude additional products will apply as of January 1, 2021 until March 31, 2021. U.S. Customs and Border Protection (CBP) will issue instructions on entry guidance and implementation.  The complete notice from the USTR may be found here.

A.N. Deringer, Inc. will continue to monitor Section 301 Exclusions announcements and CBP’s entry guidance.  Should you have any further questions regarding your specific shipments, please contact Deringer’s Compliance Department.